Excellent, excellent news from Eisai today!
"Eisai today presented new data on the investigational subcutaneous formulation of LEQEMBI showing that it clears 14% more amyloid plaques as measured by PET compared to intravenous infusion (IV), with pharmacokinetics (AUC) 11% higher and similar ARIA rates. An additional analysis of the phase 3 Clarity AD data for LEQEMBI in the PET low tau population revealed that 76% of patients in the low tau population showed no decline and 60% showed clinical improvement at 18 months of treatment."
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.72 |
Change
-0.090(4.99%) |
Mkt cap ! $291.1M | |||
| Open | High | Low | Value | Volume |
| $1.81 | $1.81 | $1.69 | $138.9K | 78.66K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | $1.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 600 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |